Riskpilot← Back to searchSign inGet full accessCD9 ApS
APSActiveCVR 28127146Nordvestvej 31Buying and selling of own real estate · NACE 6811Est. 2004— employees
Revenue 2024
DKK -989K
+99% vs 2023
EBITDA margin
100.0%
-99% vs 2023
Equity ratio
-1.3%
Financial strength
Net profit 2024
DKK -1,1M
-59% vs 2023
| Revenue | DKK -989K | +99% |
| EBITDA | DKK -989K | -99% |
| Net profit | DKK -1,1M | -59% |
| Total assets | DKK 49,8M | +392% |
| Equity | DKK -667K | -251% |
| Employees | — | — |
Legal name
CD9 ApS
CVR number
28127146
Legal form
Anpartsselskab
NACE code
6811 · Buying and selling of own real estate
Founded
15. oktober 2004
Share capital
DKK 125.000
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsesformanden alene eller af en direktør i forening med bestyrelsens næstformand eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive køb, salg og udlejning af fast ejendom, ejendomsudvikling samt anden dermed efter bestyrelsens skøn beslægtet virksomhed.
Address
Nordvestvej 31
Phone
+4533323035
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27 | — | — | — | -213 | -217 | -235 | -211 | -216 | -260 | -379 | -497 | -989 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 274 | 0 | 0 | 0 | -213 | -217 | -235 | -211 | -216 | -260 | -379 | -497 | -989 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 274 | 0 | 0 | 0 | -213 | -217 | -235 | -211 | -216 | -260 | -379 | -497 | -989 |
| Net financials | -129 | 0 | 0 | 0 | -54 | -45 | -43 | -286 | -299 | -311 | -317 | -399 | -434 |
| Profit before tax | 144 | 0 | 0 | 0 | -267 | -262 | -278 | -496 | -515 | -571 | -696 | -896 | -1.422 |
| Tax | 36 | -0 | -0 | -0 | -54 | -58 | -61 | -114 | -113 | -121 | -153 | -197 | -313 |
| Net profit | 108 | 0 | 0 | 0 | -213 | -204 | -217 | -382 | -401 | -451 | -543 | -699 | -1.109 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 9.146 | 0 | 0 | 0 | 9.511 | 9.510 | 9.493 | 9.522 | 9.482 | 9.675 | 9.792 | 10.135 | 49.825 |
| Equity | 1.179 | 0 | 0 | 0 | 339 | 135 | 918 | 536 | 135 | 684 | 141 | 442 | -667 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | -7.967 | 0 | 0 | 0 | 9.172 | 9.375 | 8.575 | 8.986 | 9.348 | 8.991 | 9.651 | 9.693 | 50.493 |
| Total debt | -7.967 | 0 | 0 | 0 | 9.172 | 9.375 | 8.575 | 8.986 | 9.348 | 8.991 | 9.651 | 9.693 | 50.493 |
EBITDA margin
-98855100.0%
This company
15.8%
Market median
-625665290% vs market
20122024
Equity ratio
-1.3%
This company
38.2%
Market median
-103% vs market
20122024
Return on equity
-110945600.0%
This company
18.4%
Market median
-602965317% vs market
20122024
Net profit margin
-110945600.0%
This company
8.1%
Market median
-1369698865% vs market
20122024
Asset turnover
-0.02×
This company
1.12×
Market median
-102% vs market
20122024
Debt / equity
75.66×
This company
0.62×
Market median
-12103% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AL Management | Management | 2024 | — | — |
UB Management | Management | 2004 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2021 | — | — | |
| Deputy Chairman | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
ApS af 25.06.2021 | Company | 100.0% | 100.0% | 2026 |
CARL EJLER RASMUSSEN & CO. A/S | Company | 100.0% | 100.0% | 2022 |
A/S AF 26.10.1983 | Company | 100.0% | 100.0% | 2018 |
| Individual | 10.0% | 10.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Carl Ejler Rasmussens Fond
CD9 ApS Board members of CD9 ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Lomholt Dinnsen | Management | 0 companies |
| Ulrik Bebe | Management | 0 companies |
| Carl Ejler Rasmussen | Chairman | 0 companies |
| Ernst Michaelsen | Deputy Chairman | 0 companies |